2023-07-18 15:30:59
LOS ANGELES, July 18 (Xinhua) — The U.S. Food and Drug Administration (FDA) has approved a new drug called Beyfortus to prevent infants and toddlers from the respiratory syncytial virus (RSV). RSV is a virus that causes respiratory diseases in people of all age groups.
Beyfortus is a monoclonal antibody that has shown to be active against RSV. It is specifically approved for use in newborns, infants born during the first RSV season, and children up to 24 months of age who remain at risk for severe RSV during the second RSV season.
According to John Farley, director of the Bureau of Infectious Diseases at the Drug Evaluation and Research Center of the FDA, RSV can cause serious diseases and lead to hospitalizations in infants and children. The approval of Beyfortus aims to reduce the impact of RSV on children, families, and the healthcare system.
While most infants and young children experience mild flu-like symptoms when infected with RSV, some babies may suffer from lower respiratory tract diseases such as pneumonia and bronchiolitis, especially during their first infection. The American Academy of Pediatrics reveals that approximately 1-3 percent of children under 12 months in the United States are admitted to the hospital each year due to the RSV virus.
The approval of Beyfortus provides a new solution to prevent RSV in infants and toddlers. This development is expected to significantly reduce the number of hospitalizations and improve the overall health of young children.
For more information and to download the clip, please contact the respective team.]
#approves #drug #prevent #RSV #virus #infants #children